OxiGene Inc (OXGN)

0.71
0.01 1.53
NASDAQ : Health Care
Prev Close 0.70
Open 0.70
Day Low/High 0.70 / 0.71
52 Wk Low/High 0.49 / 1.40
Volume 8.09K
Avg Volume 534.20K
Exchange NASDAQ
Shares Outstanding 26.54M
Market Cap 18.58M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OXiGENE Reports 2015 Financial Results

OXiGENE Reports 2015 Financial Results

OXiGENE Announces Positive Initial Data From Phase 1b Study Of CA4P In Combination With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer

OXiGENE Announces Positive Initial Data From Phase 1b Study Of CA4P In Combination With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer

-- Based on Positive Safety Data and Preliminary Signs of Efficacy, Study Expected to Advance to Phase 2 Portion in Early 2016 --

OXiGENE Appoints Matthew M. Loar As Chief Financial Officer

OXiGENE Appoints Matthew M. Loar As Chief Financial Officer

Adds Broad Finance and Operating Experience to Company's New Leadership

OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

OXiGENE (OXGN) shares are rising after the company announced that the FDA gave preliminary approval for the method of its phase 3 cancer treatment study.

OXiGENE Appoints Bill Schwieterman, M.D., As President And Chief Executive Officer

OXiGENE Appoints Bill Schwieterman, M.D., As President And Chief Executive Officer

Dai Chaplin Becomes Chief Scientific Officer

OXiGENE Reports First Quarter 2015 Financial Results

OXiGENE Reports First Quarter 2015 Financial Results

Strengthened Cash Position; Fosbretabulin and OXi4503 Clinical Programs Advancing